BR112019023592A8 - Formas cristalinas de seletalisibe - Google Patents

Formas cristalinas de seletalisibe

Info

Publication number
BR112019023592A8
BR112019023592A8 BR112019023592A BR112019023592A BR112019023592A8 BR 112019023592 A8 BR112019023592 A8 BR 112019023592A8 BR 112019023592 A BR112019023592 A BR 112019023592A BR 112019023592 A BR112019023592 A BR 112019023592A BR 112019023592 A8 BR112019023592 A8 BR 112019023592A8
Authority
BR
Brazil
Prior art keywords
seletalisib
crystalline forms
oncological
nociceptive
neurodegenerative
Prior art date
Application number
BR112019023592A
Other languages
English (en)
Other versions
BR112019023592A2 (pt
Inventor
Lambert Jozef Jan Aerts Luc
Assaf Georges
Edmond Carly Nicolas
Adolphe Carol Cool Vincent
Delatinne Jean-Pierre
Jacques Willy Delhaye Laurent
Paul Kestemont Jean
Le Meur Sarah
Original Assignee
Ucb Biopharma Sprl
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59349914&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019023592(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl, UCB Biopharma SRL filed Critical Ucb Biopharma Sprl
Publication of BR112019023592A2 publication Critical patent/BR112019023592A2/pt
Publication of BR112019023592A8 publication Critical patent/BR112019023592A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

As formas cristalinas de seletalisibe, designadas como Forma B e Forma F, e aqui caracterizadas, são inibidores seletivos das enzimas PI3 quinase, em particular da isoforma PI3Kd humana, são adequadamente benéficas na medicina, por exemplo, no tratamento de doenças inflamatórias, autoimunes, cardiovasculares, neurodegenerativas, metabólicas, oncológicas, nociceptivas ou oftálmicas.
BR112019023592A 2017-06-02 2018-05-24 Formas cristalinas de seletalisibe BR112019023592A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1708856.8A GB201708856D0 (en) 2017-06-02 2017-06-02 Seletalisib crystalline forms
GB1708856.8 2017-06-02
PCT/EP2018/063640 WO2018219772A1 (en) 2017-06-02 2018-05-24 Crystalline forms of seletalisib

Publications (2)

Publication Number Publication Date
BR112019023592A2 BR112019023592A2 (pt) 2020-05-26
BR112019023592A8 true BR112019023592A8 (pt) 2023-05-09

Family

ID=59349914

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019023592A BR112019023592A8 (pt) 2017-06-02 2018-05-24 Formas cristalinas de seletalisibe

Country Status (17)

Country Link
US (1) US11059820B2 (pt)
EP (1) EP3630760A1 (pt)
JP (1) JP7264829B2 (pt)
KR (1) KR102591329B1 (pt)
CN (2) CN114573580A (pt)
AR (1) AR112062A1 (pt)
AU (1) AU2018276243B2 (pt)
BR (1) BR112019023592A8 (pt)
CA (1) CA3062533A1 (pt)
CL (1) CL2019003510A1 (pt)
CO (1) CO2019014026A2 (pt)
EA (1) EA201992839A1 (pt)
GB (1) GB201708856D0 (pt)
IL (1) IL270937A (pt)
MX (1) MX2019013518A (pt)
RU (1) RU2019143761A (pt)
WO (1) WO2018219772A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
GB0428475D0 (en) * 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
AR082799A1 (es) 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
CA2944611A1 (en) * 2014-05-27 2015-12-03 Almirall, S.A. Addition salts of (s)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrile
GB201506786D0 (en) 2015-04-21 2015-06-03 Ucb Biopharma Sprl Therapeutic use
GB201608797D0 (en) 2016-05-19 2016-07-06 Ucb Biopharma Sprl Therapeutic use

Also Published As

Publication number Publication date
CA3062533A1 (en) 2018-12-06
EP3630760A1 (en) 2020-04-08
US11059820B2 (en) 2021-07-13
KR102591329B1 (ko) 2023-10-18
US20200095246A1 (en) 2020-03-26
BR112019023592A2 (pt) 2020-05-26
EA201992839A1 (ru) 2020-04-08
AU2018276243A1 (en) 2019-12-19
RU2019143761A (ru) 2021-07-09
MX2019013518A (es) 2020-02-10
KR20200012902A (ko) 2020-02-05
IL270937A (en) 2020-01-30
CL2019003510A1 (es) 2020-04-17
AR112062A1 (es) 2019-09-18
JP7264829B2 (ja) 2023-04-25
CN110709399A (zh) 2020-01-17
JP2020521793A (ja) 2020-07-27
CO2019014026A2 (es) 2020-01-17
CN114573580A (zh) 2022-06-03
AU2018276243B2 (en) 2021-11-25
WO2018219772A1 (en) 2018-12-06
GB201708856D0 (en) 2017-07-19

Similar Documents

Publication Publication Date Title
CR20190558A (es) Método de fabricación de anticuerpos bispecíficos, anticuerpos bispecíficos y uso terapéutico de dichos anticuerpos
BR112016012242A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
BR112016011792A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016012990A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
BR112016029630A2 (pt) derivados heteroaromáticos bicíclicos fundidos como inibidores de inibidores de cinase
CR20170167A (es) Derivados de imidazol pentacíclicos fusionados
BR112016016916A2 (pt) método de tratamento de angiodema hereditário (hae)
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
BR112013004750A2 (pt) derivados de quinolina e quinoxalina como inibidores da cinase
BR112016011794A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX2017007852A (es) Formulaciones de acido hipocloroso y metodos para tratar afecciones de la piel.
BR112018008017A2 (pt) composição farmacêutica, método de preparação de composição farmacêutica líquida, kit farmacêutico, sistema de fornecimento de injeção
BR112016012258A2 (pt) Derivados de tetra-hidrobenzimidazol como moduladores de atividade de tnf
CL2015002620A1 (es) Derivados piridin-4-ilo
MX2023008211A (es) Composiciones y metodos para disminuir la expresion de tau.
BR112016029632A2 (pt) derivados heteroaromáticos bicíclicos fundidos como inibidores de cinase
MA52542A (fr) Thérapie cellulaire adoptive
DK3464550T3 (da) Beholdere og spinnerkobler med reduceret hjulslør til dyrkning af celler
BR112016029558A2 (pt) terapia de células-tronco em patologias endometriais
BR112016029635A2 (pt) derivados pirazolo-piridina como inibidores de quinase
EP3880151A4 (en) DETERMINATION OF THE TREATMENT RESPONSE IN SINGLE CELLS
BR112018012913A2 (pt) tratamento in situ de sementes em sulco
BR112016012261A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25D Requested change of name of applicant approved

Owner name: UCB BIOPHARMA SRL (BE)